Loes E Visser

1 INTRODUCTION For over six decades, fluoropyrimidine-containing chemotherapy has been widely used in various solid tumors, such as breast cancer and gastrointestinal cancers. However, approximately 30% of patients experience severe fluoropyrimidine-associated toxicity, including mucositis, diarrhea, hand-foot syndrome, and bone marrow toxicity [1-3].

CONFLICT OF INTEREST The authors declared no competing interests in this work. Supporting Information Filename Description cpt3574-sup-0001-TableS1.docxWord 2007 document , 32.2 KB Table S1 cpt3574-sup-0002-TableS2.docxWord 2007 document , 16.9 KB Table S2 cpt3574-sup-0003-TableS3.docxWord 2007 document , 16.4 KB Table S3 cpt3574-sup-0004-FiguresS1-S5.docxWord 2007 document , 561.7 KB Figures S1-S5 References 1 European Medicines Agency.

Antidepressants are often only moderately successful in decreasing the severity of depressive symptoms. In part, antidepressant treatment response in patients with depression is genetically determined. However, although a large number of studies have been conducted aiming to identify genetic variants associated with antidepressant drug response in depression, only a few variants have been repeatedly identified.